Eli Lilly and Boehringer Ingelheim’s (BI) Jardiance will continue to increase its market share across the heart failure (HF) and type 2 diabetes (T2D) space following the release of data from the Emperor-Preserved trial, according to GlobalData. The leading data and analytics company notes that Jardiance’s demonstration of significant efficacy in patients with both heart failure (HF) and chronic kidney disease (CKD) is particularly influential and has already led to increased competition in the sodium-glucose co-transporter-2 inhibitor (SGLT-2I) market.

Akash Patel, Pharma Analyst at GlobalData, comments: “The number of CKD, T2D and HF patients is rising in the US, with these expected to increase by 0.99%, 2.89% and 2.24%, respectively, according to GlobalData’s epidemiology database. Any new advancements in these areas are greatly welcomed by physicians, and Jardiance should comfortably gain market share. Being a SGLT-2I is also an advantage for Jardinance, as key opinion leaders (KOLs) interviewed by GlobalData have expressed their enthusiasm at cardiorenal data relating to the SGLT2I class. These novel data will likely prove significant to the US market, where large numbers of patients are developing cardiorenal and metabolic complications that often present as co-morbidities of T2D.”

The Emperor-Preserved trial demonstrated that Jardiance significantly reduces the risk of the composite primary endpoint of cardiovascular death or hospitalization in adults with HF and left-ventricular ejection fraction (LVEF) by over 40%, in comparison to the placebo group. This result was irrespective of diabetes status and offers significant promise to a type of HF patient that traditionally has been challenging to provide effective treatment for.

Patel continues: “In August 2021, the FDA approved Jardiance for the treatment of HF with reduced ejection fraction (HFrEF) and Lilly and BI have presented data demonstrating Jardiance’s effectiveness in patients with HF with preserved ejection fraction (HfpEF) with or without diabetes. Jardiance receiving FDA approval for HFpEF would enable it to be the first therapy to deliver improved outcomes across all HF patients and would gain significant market share in an increasingly crowded SGLT-2I market.”